immuno oncology frontiers world miami


Colleen Delaney

Dr Colleen Delaney

Founder and Chief Medical Officer, Nohla Therapeutics

Dr. Colleen Delaney is a Founder and the Chief Medical Officer of Nohla Therapeutics, Inc., a cellular therapy company focused on developing off-the-shelf, universal-donor therapies that require no HLA matching. 

Dr. Delaney’s research interests focus on the role of the Notch signaling pathway in hematopoietic stem cell regulation and ex-vivo expansion of umbilical cord blood stem and progenitor cells for clinical applications. Her group has developed a novel and clinically feasible method for the ex vivo expansion of cord blood derived hematopoietic stem and progenitor cells in the presence of Notch ligands. This work was translated into a novel pilot study investigating the use of ex vivo expanded cord blood progenitors to augment conventional cord blood transplantation. She has since extended this work to investigate the potential of cryopreserved, non-HLA matched “off the shelf” ex vivo expanded cord blood progenitor cells to provide rapid but transient myeloid reconstitution in the setting of cord blood transplant and following dose-intensive chemotherapy.

Dr. Delaney is a Member and the Madeline Dabney Adams Endowed Chair in AML Research of the Fred Hutchinson Cancer Research Center Clinical Research Division, and an Associate Professor at the University of Washington in the Department of Pediatrics, Division of Pediatric Hematology/Oncology. She is an attending physician at Seattle Children’s Hospital and the Seattle Cancer Care Alliance, and she established and directs the Cord Blood Transplant Program at Fred Hutch/SCCA. 

She is the recipient of several prestigious awards, including the Damon Runyon Clinical Investigator Award, Seattle Top Doctor Award 2011/2012, the Dr. Ali Al-Johani Award in recognition of exemplary clinical medical care and compassion to patients and families in 2013, and the 2016 Leaders in Health Care: Outstanding Medical Research Award from Seattle Business Magazine. She also serves on the Board of Directors for ASBMT, is a founding member and on the Board of Directors for the Cord Blood Association, and is a standing NIH grant review committee member.

She holds a bachelor’s degree in Molecular Biology and Biochemistry from Wesleyan University, a MSc in Social Research and Social Policy from Oxford University, and a M.D. from Harvard Medical School. Colleen did her residency in General Pediatrics at the University of California, San Francisco and a Fellowship in Pediatric Hematology/Oncology at Fred Hutchinson Cancer Research Center/ Seattle Children’s Hospital and Regional Medical Center. 

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy